Clinical Trial Update: Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery [Phase 1]

View source ↗

Summary

Phase 1 trial of AVB-620 in women with primary, non-recurrent breast cancer undergoing surgery has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AVB-620

Snippet

Sponsor: Avelas Biosciences, Inc. | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED